C-C motif chemokine ligand 2
C-C motif chemokine ligand 2 (CCL2), widely known as Monocyte Chemoattractant Protein-1 (MCP-1), is a small secreted cytokine belonging to the CC chemokine family.
C-C motif chemokine ligand 2 (CCL2), widely known as Monocyte Chemoattractant Protein-1 (MCP-1), is a small secreted cytokine belonging to the CC chemokine family. It is encoded by the CCL2 gene and functions primarily as a potent chemoattractant that recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury, infection, and inflammation. CCL2 exerts its effects predominantly through binding to its cognate receptor CCR2, triggering downstream signaling cascades that promote immune cell trafficking across vascular endothelium into inflamed tissues. As a central mediator of the innate and adaptive immune response, CCL2 is constitutively expressed at low levels in a wide range of cell types — including endothelial cells, smooth muscle cells, fibroblasts, astrocytes, and adipose-derived stem cells — and is rapidly upregulated in response to proinflammatory stimuli such as TNF (Tnf-α), interleukin-1 beta, Interleukin-6 (IL-6), and nuclear factor kappa B (NF-κB) activation.
Beyond its canonical role in monocyte recruitment, CCL2 has emerged as a pleiotropic signaling molecule with relevance across a broad spectrum of pathological conditions, including sepsis, chronic kidney disease, lupus nephritis, obesity-associated inflammation, periodontitis, spinal cord injury, diabetic wound healing, and cancer. Its intersection with oxidative stress pathways, matrix metalloproteinase activity (notably Matrix Metalloproteinase-9 (MMP-9)), and growth factors such as TGF-β1 positions it as a critical node in the inflammatory-fibrotic axis. Dysregulated CCL2 expression is increasingly recognized as both a biomarker of disease severity and a tractable therapeutic target, making it a subject of intense contemporary biomedical research.
Where the papers sit
10 papers from the last 6 months study C-C motif chemokine ligand 2 directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 1 observational · 1 human data · 3 preclinical · 4 unclassified
Themes 3 themes
-
Macrophage Immune Suppression
Macrophage recruitment and immune suppression are central across glioblastoma, lung adenocarcinoma, and other inflammatory settings. Radiotherapy-induced chemokines are being redirected with molecular decoys, while ASP1012 seeks durable memory T-cell responses. Multi-omics studies prioritize GINS1, the CCL2/TIMP1 axis, and microbiota-derived metabolites as prognostic or immune-regulatory markers. The recurring goal is to convert suppressive microenvironments into more responsive ones, but validation beyond computational associations remains open.
5 papers · 50%
-
Chemokine-Linked Inflammation
Chemokine-linked inflammation appears in breast-tumor treatment, chemotherapy-associated cytokine changes, and Glaesserella parasuis infection. CCL2/CCL8 diphtheria-toxin peptides represent a targeted cytotoxic approach in breast tumors. Exercise during chemotherapy is being assessed through systemic cytokine and muscle-autophagy responses. No unified direction is evident beyond connecting chemokine signatures with immune or inflammatory states.
3 papers · 30%
-
Early Kidney Injury
Early detection and prevention of kidney injury dominate this work. ANGPT2, LCN2, glomerular filtration rate, and urea are evaluated as indicators of renal damage and progression in Chagas disease. Anti-CCL2-conjugated platelets reduce monocyte infiltration during allograft and ischemia-reperfusion injury. The field is moving toward combining biomarker surveillance with targeted control of inflammatory recruitment, although broader clinical validation remains needed.
2 papers · 20%
Papers
The 10 papers from the last 6 months that study C-C motif chemokine ligand 2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Macrophage Immune Suppression (5)
- Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
- Exploratory multi-omics links CCL2/TIMP1 axis to immunosuppressive TME in glioblastoma. Cell cycle (Georgetown, Tex.) · 15 Jul 2026 PMID 42454783
- The oncolytic viral immunotherapy ASP1012 optimizes memory T cell responses after systemic delivery. Molecular therapy : the journal of the American Society of Gene Therapy · 9 Jul 2026 PMID 42421317
- Hijacking radiotherapy-induced chemokines with self-assembled molecular decoys for glioblastoma radio-immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 2 Jul 2026 PMID 42392408
- Multi-omics analysis identifies GINS1 as a prognostic biomarker in lung adenocarcinoma, linked to macrophage polarization and tumor cell survival. Discover oncology · 15 Jun 2026 PMID 42295485
Chemokine-Linked Inflammation (3)
- Integration of bulk RNA-seq and scRNA-seq reveals cell subsets and gene signatures associated with Glaesserella parasuis infection. BMC genomics · 7 Jul 2026 PMID 42410501
- Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides. Cancer biology & therapy · 2 Jul 2026 PMID 42390481
- The Effect of Strength Training During Chemotherapy in Women With Breast Cancer on Serum Cytokine Concentrations and Skeletal Muscle Autophagy-Related Proteins. European journal of sport science · 25 Jun 2026 PMID 42350900
Early Kidney Injury (2)
- Renal and endothelial biomarkers in Chagas disease in the Brazilian Amazon region: Early indicators of kidney injury and disease progression. PloS one · 17 Jul 2026 PMID 42467670
- Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration. Journal of hepatology · 1 Jul 2026 PMID 42385858
By study type
Clinical trials (1)
- The Effect of Strength Training During Chemotherapy in Women With Breast Cancer on Serum Cytokine Concentrations and Skeletal Muscle Autophagy-Related Proteins. European journal of sport science · 25 Jun 2026 PMID 42350900
Observational studies and case reports (1)
- Renal and endothelial biomarkers in Chagas disease in the Brazilian Amazon region: Early indicators of kidney injury and disease progression. PloS one · 17 Jul 2026 PMID 42467670
Human data, design not indexed (1)
- Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
Preclinical: animal, cell and lab studies (3)
- The oncolytic viral immunotherapy ASP1012 optimizes memory T cell responses after systemic delivery. Molecular therapy : the journal of the American Society of Gene Therapy · 9 Jul 2026 PMID 42421317
- Hijacking radiotherapy-induced chemokines with self-assembled molecular decoys for glioblastoma radio-immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 2 Jul 2026 PMID 42392408
- Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides. Cancer biology & therapy · 2 Jul 2026 PMID 42390481
Unclassified: not yet indexed with MeSH (4)
- Exploratory multi-omics links CCL2/TIMP1 axis to immunosuppressive TME in glioblastoma. Cell cycle (Georgetown, Tex.) · 15 Jul 2026 PMID 42454783
- Integration of bulk RNA-seq and scRNA-seq reveals cell subsets and gene signatures associated with Glaesserella parasuis infection. BMC genomics · 7 Jul 2026 PMID 42410501
- Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration. Journal of hepatology · 1 Jul 2026 PMID 42385858
- Multi-omics analysis identifies GINS1 as a prognostic biomarker in lung adenocarcinoma, linked to macrophage polarization and tumor cell survival. Discover oncology · 15 Jun 2026 PMID 42295485
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.